Bailard Inc. Makes New Investment in LENSAR, Inc. (NASDAQ:LNSR)

Bailard Inc. bought a new stake in shares of LENSAR, Inc. (NASDAQ:LNSR) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 20,256 shares of the company’s stock, valued at approximately $181,000.

Separately, Evernest Financial Advisors LLC acquired a new stake in LENSAR in the fourth quarter valued at approximately $174,000. Institutional investors own 40.15% of the company’s stock.

LENSAR Stock Performance

NASDAQ:LNSR opened at $15.34 on Thursday. The company has a fifty day moving average of $9.91 and a two-hundred day moving average of $7.29. LENSAR, Inc. has a fifty-two week low of $2.67 and a fifty-two week high of $16.40. The stock has a market capitalization of $180.84 million, a PE ratio of -10.51 and a beta of 0.62.

LENSAR (NASDAQ:LNSR) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($1.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.40). LENSAR had a negative net margin of 34.03% and a negative return on equity of 49.02%. The company had revenue of $16.73 million during the quarter, compared to analysts’ expectations of $14.95 million.

Analyst Ratings Changes

Separately, Lake Street Capital upped their target price on LENSAR from $12.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, February 28th.

About LENSAR

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.